Related by context. All words. (Click for frequent words.) 82 pivotal Phase 75 placebo controlled Phase 74 Phase 1b 73 multicenter Phase 73 pivotal Phase III 73 Phase III clinical 73 dose escalation trial 72 randomized controlled Phase 72 Phase 2b clinical 71 phase IIb 71 Phase IIb 71 Phase Ib 71 Phase 2b study 70 phase IIb clinical 70 randomized Phase III 70 Phase 2a clinical 69 Phase 2b trial 69 Phase 2b 69 dose escalation Phase 69 Phase III randomized 68 Phase 2a 68 multicenter Phase II 68 Phase 1b clinical 68 Phase IIb clinical 68 registrational trial 68 Phase III 68 Phase Ib clinical 68 NO# [002] 67 multicenter phase 67 Phase 2a trial 67 Phase Ib II 67 randomized Phase 2b 67 LUX Lung 66 Phase 1b trial 66 phase Ib 66 randomized multicenter 66 Phase Ia 66 Phase IIa clinical 66 Phase 66 Phase IIb trial 66 phase IIa clinical 66 Phase IIa trial 66 randomized placebo controlled 66 axitinib 66 dose escalation study 66 SUCCEED trial 65 registrational 65 dose escalation 65 multicenter randomized double 65 multicenter clinical 65 phase IIa 65 PRECiSE 65 Phase III pivotal 65 placebo controlled Phase III 65 glufosfamide 65 phase 2a 64 multicenter Phase III 64 Phase 1a 64 PRE SURGE 64 HGS ETR1 64 Phase IIIb clinical 64 ongoing Phase 1b 64 Phase III clinical trials 64 multicenter 64 randomized double 64 double blinded placebo 64 oral ridaforolimus 64 clinical trial 64 Phase IIIb 64 relapsed refractory multiple myeloma 63 elacytarabine 63 double blinded randomized 63 BRIM2 63 multiple ascending dose 63 dose escalation clinical 63 Phase IIa 63 HCV SPRINT 63 Phase II 63 multicenter randomized 63 relapsed multiple myeloma 63 oral deforolimus 63 Randomized Phase 63 placebo controlled 63 randomized controlled 63 dose cohorts 63 Phase IIb trials 63 afatinib 63 Amrubicin 62 HER2 positive metastatic breast 62 label multicenter 62 Phase Ib study 62 viral kinetic 62 dose cohort 62 APEX PD 62 IMC A# 62 obatoclax 62 hormone refractory prostate cancer 62 alvespimycin 62 label dose escalation 62 ganetespib 61 Phase III trials 61 custirsen 61 dirucotide 61 Dacogen injection 61 pharmacokinetic PK study 61 multicentre randomized 61 label multicenter Phase 61 evaluable patients 61 BRIM3 61 Phase Ib clinical trials 61 double blind placebo 61 multicentre 61 multicenter randomized Phase 61 ASA# 61 Pivotal Phase 61 prospective randomized 61 ofatumumab 61 sunitinib malate 61 placebo controlled randomized 61 RE SURGE 61 treatment naive genotype 61 OncoVEX GM CSF 61 IMA# 61 Phase 2b randomized 61 randomized clinical 61 initiate Phase 61 ADVANCE PD 61 TMC# C# 61 JAK inhibitor 61 prospective randomized placebo 61 ToGA 61 elotuzumab 60 blind randomized placebo 60 TELCYTA 60 sunitinib 60 treatment naïve genotype 60 APPRAISE 60 pralatrexate 60 CLL8 60 BAY #-# 60 lintuzumab 60 phase IIb trial 60 satraplatin Phase 60 docetaxel Taxotere R 60 prospective multicenter 60 voreloxin 60 CR# vcMMAE 60 sapacitabine 60 docetaxel chemotherapy 60 metastatic hormone refractory 60 Phase IIa trials 60 randomized Phase IIb 60 ELACYT 60 Initiated Phase 60 T DM1 60 adecatumumab 60 Alpharadin 60 multicenter randomized placebo controlled 60 Cloretazine R VNP#M 60 rALLy clinical trial 60 multicenter randomized controlled 60 PDX pralatrexate 60 confirmatory Phase III 60 ascending dose 60 nab paclitaxel 60 ZYBRESTAT 60 HGS# 60 platinum refractory 60 Phase #/#a 60 tesmilifene 59 INCB# [001] 59 tanespimycin 59 phase Ib clinical 59 FOLOTYN ® 59 neratinib 59 IMGN# 59 COMFORT II 59 metastatic castrate resistant 59 Sorafenib HCC Assessment 59 Phase 2b clinical trials 59 FOLOTYN 59 AVADO 59 sorafenib Nexavar ® 59 controlled multicenter 59 L BLP# 59 Phase #/#a trial 59 carfilzomib 59 Proxinium TM 59 randomized controlled clinical 59 phase IIb study 59 Phase III Pivotal 59 AEG# 59 nimotuzumab 59 perifosine 59 BCIRG 59 panitumumab 59 IIa trial 59 confirmatory Phase 3 59 Phase #b/#a 59 refractory AML 59 Sym# 59 refractory CLL 59 Amigal 59 HuMax EGFr 59 NSCLC 58 CoFactor 58 randomized 58 ZYBRESTAT fosbretabulin 58 Phase IIB 58 EFAPROXYN 58 aflibercept 58 forodesine 58 PROPEL trial 58 confirmatory clinical 58 pertuzumab 58 Imprime PGG 58 European Sepsis Trial 58 EOquin TM 58 metastatic HRPC 58 CA4P 58 Tanespimycin 58 Phase IIIb study 58 placebo controlled clinical 58 REOLYSIN ® 58 dose dose escalation 58 L MTP PE 58 deforolimus 58 BR.# 58 Allovectin 7 ® 58 GetGoal Phase III 58 phase IIb III 58 Phase IIb clinical trials 58 ENDEAVOR IV 58 Urocidin 58 dosing cohorts 58 prospective randomized multicenter 58 TNFerade 58 investigational pan BCR 58 EDEMA4 58 Initiate Phase 58 PXD# 58 Phase III placebo controlled 58 Vicinium TM 58 crizotinib PF # 58 Phase 1a clinical 58 Phase #b/#a clinical 58 evaluating tivozanib 58 RG# [001] 58 Genasense ® 58 farletuzumab 58 PEG Interferon lambda 58 Zerenex 58 stage IIIB 58 MEK inhibitor RDEA# 58 Azedra 58 leading oral taxane 58 randomized multicentre 58 tivozanib 58 IMPACT IMmunotherapy 58 Investigational Device Exemption IDE 58 vinorelbine 58 relapsed refractory 58 single ascending dose 58 AQ4N 58 pivotal bioequivalence 58 TLK# 58 TG MV 58 unblinded 58 trastuzumab DM1 T DM1 58 ThermoDox 58 MDV# 58 evaluating REVLIMID 58 veltuzumab 58 ThermoDox ® 58 blind randomized 58 IMC #B 57 monotherapy 57 HGS ETR2 57 Phase 2b kidney transplant 57 multicentre randomized double 57 Marqibo 57 ZACTIMA 57 tolerability 57 pomalidomide 57 talactoferrin 57 RDEA# 57 Bezielle 57 refractory multiple myeloma 57 blinatumomab 57 picoplatin 57 TMC# [002] 57 metastatic CRPC 57 belinostat 57 randomized multicenter Phase III 57 clinical trials 57 ILLUMINATE 57 Phase III VISTA 57 vandetanib 57 metastatic colorectal cancer 57 XL# SAR# 57 Perifosine 57 resistant ovarian cancer 57 tolevamer 57 XL# [003] 57 multicenter placebo controlled 57 Pivotal Trial 57 edoxaban 57 RIBBON 57 rNAPc2 57 phase IIIb 57 zanolimumab 57 AP# [003] 57 metastatic renal cell carcinoma 57 Tarceva TM 57 Clolar ® 57 Dapagliflozin 57 clofarabine 57 blinded randomized placebo controlled 57 teriflunomide 57 Carfilzomib 57 HuMax CD4 57 AEGR 57 Randomized Phase II 57 huC# DM4 57 ofatumumab HuMax CD# 57 Phase 1b clinical trials 57 Augment Injectable 57 SPIRIT IV 57 EOquin TM phase 57 Alocrest 57 MabCampath 57 antibody MAb 57 docetaxel 57 peginesatide 57 Vectibix 57 mipomersen 57 prospective randomized controlled 57 ACTEMRA TM 57 ThermoDox R 57 enzastaurin 57 HCD# [002] 57 MGCD# [001] 57 Phase III randomized controlled 57 Viramidine 57 EDEMA3 57 Genz # 57 EVEREST II 57 imetelstat GRN#L 57 masked placebo controlled 57 standard chemotherapy regimen 57 valopicitabine 57 IV metastatic melanoma 57 multicenter prospective 57 ACTEMRA 57 PSMA ADC 57 CALGB 57 TRISENOX 57 R#/MEM # 57 label multicenter randomized 57 sorafenib 57 entinostat 57 plus dexamethasone 57 investigational compound 57 EndoTAG TM -1 57 pharmacokinetic PK 57 VEGF Trap 56 brivaracetam 56 ALN VSP Phase 56 ABSORB trial 56 confirmatory Phase 56 virus HCV protease inhibitor 56 rALLy trial 56 pegylated interferon alpha 56 YONDELIS 56 PROSTVAC TM 56 AIR CF2 56 Xanafide 56 prospective multicenter randomized 56 Phase 1b dose escalation 56 Allovectin 7 56 eculizumab 56 LibiGel Phase III 56 liposomal formulation 56 PHX# 56 TACI Ig 56 ixabepilone 56 SPIRIT III 56 mapatumumab 56 pralatrexate injection 56 follicular NHL 56 DASISION 56 metastatic castration resistant 56 multicenter study 56 unresectable stage 56 refractory metastatic colorectal cancer 56 ANCHOR trial 56 ISIS # 56 trastuzumab emtansine T DM1 56 oritavancin 56 VELCADE 56 EOquin 56 FAME Study 56 GRN#L 56 teduglutide 56 PS# [001] 56 NCCTG 56 FavId 56 trastuzumab Herceptin R 56 CTA# Injection 56 INCB# [002] 56 PROPEL 56 comparing alemtuzumab 56 Allovectin 7 R 56 Taxotere ® 56 GALNS 56 bendamustine 56 BiovaxID 56 mCRC 56 OHR/AVR# 56 Exherin TM 56 castrate resistant prostate cancer 56 Fx #A 56 ERBITUX 56 Asentar 56 randomized controlled multicenter 56 CRLX# 56 investigational drug 56 SCH # 56 ocrelizumab 56 Phase IIb III 56 CLARITY study 56 anticancer compound 56 zalutumumab 56 vicriviroc 56 Aplidin 56 Insegia 56 antitumor activity 56 pegloticase 56 TAXUS ATLAS 56 cutaneous T cell 56 investigational monoclonal antibody 56 nitazoxanide 56 Zybrestat 56 Prostate AdenoCarcinoma Treatment 56 EndoTAG 56 celgosivir 56 recurrent NSCLC 56 tremelimumab 56 Plicera 56 TORISEL 56 subcutaneous formulation 56 Board DSMB 56 Hepatocellular Carcinoma HCC 56 IDX# 56 Phase III HEAT 56 RE LY 56 REOLYSIN 56 pharmacokinetics PK 56 relapsing multiple sclerosis 56 blinded randomized 56 HCV RESPOND 2 55 MOZOBIL 55 recurrent glioblastoma 55 Ozarelix 55 Phenoptin 55 Virulizin ® 55 PRX # 55 CIMZIA TM 55 satraplatin 55 Folotyn 55 CRMD# 55 Telatinib 55 HspE7 55 temsirolimus 55 LBH# 55 Ceflatonin R 55 PSN# [002] 55 IIa clinical trial 55 investigational compounds 55 ATTRACT 55 initiate Phase IIb 55 Aflibercept 55 SAR# [004] 55 Cloretazine ® 55 PERSEUS 55 Omacetaxine 55 active comparator 55 nonrandomized 55 assessing T DM1 55 APTIVUS 55 tolerated dose MTD 55 superficial bladder cancer 55 PANVAC VF 55 lomitapide 55 Telcyta 55 ProLindac 55 romidepsin 55 castration resistant prostate cancer 55 PEG PAL 55 CD# antibody [001] 55 Quinamed 55 AzaSite Plus 55 Phase III metastatic melanoma 55 ENDEAVOR III 55 ponatinib 55 StemEx R 55 velafermin 55 oral sapacitabine 55 RSD# oral 55 RGB # 55 ascending doses 55 visilizumab 55 palifosfamide 55 metastatic RCC 55 brentuximab vedotin 55 Tarvacin TM 55 tesetaxel 55 PEG SN# 55 Phase III confirmatory 55 PRTX 55 heavily pretreated 55 HCV genotype 55 recurrent ovarian cancer 55 lintuzumab SGN 55 LUMINATE 55 safety tolerability pharmacokinetics 55 mitogen activated ERK kinase 55 BLA submission 55 Advaxis Phase 55 lumiliximab 55 FOLFOX 55 multicenter multinational 55 mGluR5 negative 55 lorcaserin Phase 55 Combination REOLYSIN R 55 adecatumumab MT# 55 REVLIMID lenalidomide 55 Glufosfamide 55 GOUT 55 eniluracil 55 MERLIN TIMI 55 Clolar 55 phase III ACCLAIM 55 RE LY ® 55 pharmacodynamics 55 PROVENGE sipuleucel T 55 Phase #b/#a trial 55 Reolysin 55 nonclinical studies 55 Ceflatonin 55 GLP toxicology studies 55 Ixempra 55 Archexin 55 fosbretabulin 55 metastatic melanoma 55 neoadjuvant 55 Tavocept 55 TEMSO 55 PI3K/Akt pathway inhibitor 55 Laquinimod 55 Myocet 55 advanced NSCLC 55 controlled multicenter Phase 55 systemic ALCL 55 DSMB 55 interferon gamma 1b 55 IV NSCLC 55 PRT# 55 HCV protease inhibitor 55 GVAX 55 evaluating Xcytrin 55 ADVEXIN 55 iniparib 55 ZK EPO 55 dasatinib Sprycel ® 55 anti leukemic 55 stated Michelle Berrey 55 fostamatinib 55 dacetuzumab 55 erlotinib Tarceva ® 55 multicenter randomized clinical 55 STEALTH C 55 darapladib 55 seliciclib 55 Traficet EN 55 MLN# 55 evaluating carfilzomib 55 Anturol 55 Xcellerated T Cells 55 humanized anti 55 pazopanib 55 Cotara 55 motesanib 55 radiation sensitizer 55 Daclizumab 55 omacetaxine 55 JAK1 55 Tovaxin 55 fidaxomicin Phase 55 refractory acute myeloid 54 HRPC 54 MAA submission 54 sipuleucel T 54 placebo controlled clinical trials 54 thymalfasin 54 TRO# 54 metastatic sarcomas 54 blind multicenter 54 sodium thiosulfate STS 54 Locteron ® 54 ROCKET AF 54 MEND CABG II 54 evaluating T DM1 54 Panzem R NCD 54 ALSYMPCA 54 TroVax 54 clinical pharmacology studies 54 cell lymphoma CTCL 54 pharmacokinetic 54 blind placebo controlled 54 recurrent GBM 54 including eniluracil ADH 54 MAGE A3 ASCI 54 RCW breast cancer 54 Azixa 54 cilengitide 54 myelodysplastic syndromes MDS 54 lixisenatide 54 CONSERV 54 depsipeptide 54 RADIANT 54 systemic anaplastic large 54 MEND CABG 54 BLP# Liposome Vaccine 54 Blinatumomab 54 ENESTnd 54 eprotirome 54 TELINTRA 54 relapsing remitting multiple sclerosis 54 Atiprimod 54 TTF Therapy 54 YERVOY 54 Stimuvax 54 pharmacokinetic studies 54 trabedersen 54 OncoVEX 54 DU #b 54 Jevtana 54 dosing cohort 54 BiTE R 54 elesclomol 54 Dacogen 54 carboplatin paclitaxel 54 tolerability profile 54 XIENCE V Stent System 54 Ophena TM 54 capecitabine Xeloda R 54 sorafenib tablets 54 immunosuppressive compound 54 JANUVIA 54 dependent kinase inhibitor 54 cangrelor 54 Annamycin 54 ENGAGE AF TIMI 54 telaprevir dosed 54 iclaprim 54 unique alkylating agent 54 bardoxolone 54 blinded placebo controlled 54 Diabetic Macular Edema DME 54 Phase III multicenter 54 oral formulation 54 low dose cytarabine 54 indolent NHL 54 #D#C# 54 Tesetaxel 54 Bronchitol 54 ARDIS 54 CYT# 54 budesonide MMX 54 Diamyd ® 54 Phase Ib IIa 54 IRX 2 54 GEM OS1 54 Onrigin 54 tramiprosate Alzhemed TM 54 Vitaxin 54 bile duct tumor 54 acyclovir Lauriad R 54 SUTENT 54 initiate Phase 1b 54 trastuzumab DM1 54 temozolomide 54 vascular disrupting agent 54 investigational oral 54 trodusquemine 54 ARIKACE 54 lymphoma CTCL 54 PF # [001] 54 refractory cutaneous T 54 leukemia CLL 54 Taxotere R 54 LCP Tacro 54 Genasense 54 Personalized Immunotherapy 54 SinuNase 54 hypoxia activated prodrug 54 Elagolix 54 NP2 Enkephalin 54 IIa clinical 54 mertansine 54 Cloretazine 54 BrachySil 54 phenoxodiol 54 sorafenib Nexavar 54 Targretin 54 imetelstat 54 ONTARGET 54 dalbavancin 54 MIVI III 54 BrachySil TM 54 daclizumab 54 GVAX immunotherapy 54 PrevOnco 54 carboplatin 54 prospective observational 54 BRAF inhibitor 54 Ceflatonin ® 54 hematologic malignancies 54 EMPHASIS HF trial 54 NEO3 54 Telavancin 54 multicenter trials 54 Veronate 54 PEGylated interferon beta 1a 54 mRCC 54 relapsed MM 54 RSD# iv 54 PROVENGE ® 54 dose escalation phase 54 CHAMPION PCI 54 vemurafenib 54 patients evaluable 54 oral rivaroxaban 54 Hsp# inhibitor 54 randomized blinded 54 microplasmin 54 brentuximab vedotin SGN 54 Aclidinium 54 methylnaltrexone 54 OncoVex 54 refractory gout 54 HuMax CD# 54 PFO migraine 54 MKC# MT 54 AIR CF1 54 safety tolerability 54 KRAS mutations occur 54 ADAGIO study 53 refractory Hodgkin lymphoma 53 NSABP 53 VNP#M 53 torezolid phosphate 53 gemcitabine 53 SYMMETRY trial 53 OPT CHF 53 telaprevir 53 eltrombopag 53 epratuzumab 53 COU AA 53 cediranib 53 Phase III psoriasis 53 CTAP# Capsules 53 Troxatyl 53 trabectedin 53 StemEx 53 Phase IIa clinical trials 53 ORMD 53 follicular non 53 IIb clinical trial 53 velafermin belinostat 53 CTCL 53 mg/m2 dose 53 PROMACTA 53 Celacade TM technology 53 MEK inhibitor 53 IMPACT DCM 53 Aurexis 53 EchoCRT 53 Pivotal Study 53 Tarceva erlotinib 53 dose regimens 53 midstage clinical 53 evaluating Prochymal 53 randomized clinical trials 53 gemcitabine Gemzar ® 53 unresectable 53 plus prednisone 53 randomized multicenter trial 53 Genasense oblimersen sodium Injection 53 advanced unresectable 53 registrational Phase 53 unresectable liver cancer 53 voclosporin 53 Phase 2b monotherapy 53 OPAXIO 53 Prochymal 53 recurrent glioblastoma multiforme 53 unblinding 53 pitavastatin 53 IV malignant melanoma 53 Pirfenidone 53 PRIMO CABG 53 NXL# 53 Prospective Randomized 53 CIMZIA ™ 53 LymphoStat B belimumab 53 retaspimycin 53 CEQ# 53 ORENCIA ® 53 albinterferon alfa 2b 53 DURATION 53 alvimopan 53 rindopepimut 53 pain palliation 53 evaluable 53 dosing regimens 53 Corlux 53 Second Pivotal Phase 53 pharmacodynamic 53 TG# [001] 53 dacetuzumab SGN 53 dabigatran etexilate 53 figitumumab 53 MT# MEDI 53 amrubicin 53 histone deacetylase HDAC inhibitor 53 AVOREN 53 goserelin 53 μg dose 53 arsenic trioxide injection 53 prostate cancer HRPC 53 oral prodrug 53 telomerase inhibitor drug 53 tgAAC# 53 evaluating nimotuzumab 53 inhibitor RG# 53 sodium glucose cotransporter 53 randomized #:# 53 initiated Phase Ib 53 Actemra 53 PLK1 SNALP 53 Phase IIB clinical 53 humanized monoclonal antibody 53 dacarbazine 53 preclinical efficacy 53 FORTIS M trial 53 TMC# [001] 53 investigational antiplatelet agent 53 plus ribavirin 53 Afatinib 53 ruxolitinib 53 leukemia AML 53 Triapine 53 INTERCEPT platelets 53 NSABP B 53 Mozobil 53 Matrix Phase 2b 53 drug pipeline TAFA# 53 Mipomersen 53 Fludara 53 TAXUS IV 53 IL# PE#QQR 53 BioNumerik 53 TASKi2 53 Fibrillex TM 53 Phase III ALLEGRO 53 metastatic renal cell 53 investigational humanized monoclonal antibody 53 INCB# [003] 53 myelofibrosis 53 KRN# 53 PrevOnco ™ 53 peginterferon alfa 2b 53 Degarelix 53 Xeloda ® 53 GATTEX ® 53 refractory CTCL 53 oral taxane 53 Clavis Pharma 53 AZILECT ® 53 pegylated liposomal doxorubicin 53 CALGB # [002] 53 davunetide intranasal AL 53 SinuNase TM 53 receptor tyrosine kinase inhibitor 53 ancrod 53 mCRC patients 53 cutaneous T 53 azacitidine 53 RECORD1 53 ZEVALIN 53 candidate AQ4N 53 varespladib 53 galiximab 53 OvaRex R 53 cetrorelix 53 LEVADEX 53 investigational 53 TASQ 53 Aplidin R 53 urocortin 2 53 Oral NKTR 53 Oncoscience AG 53 Pralatrexate 53 TBC# 53 safety tolerability pharmacokinetic 53 pegylated interferon alfa 2a 53 RECIST criteria 53 viral kinetics 53 SIR Spheres 53 AMR# 53 OvaRex ® MAb 53 rilonacept 53 lesinurad 53 lorvotuzumab mertansine 53 refractory indolent non 53 subanalysis 53 denufosol 53 ARRY 53 TG# [003] 53 Brentuximab Vedotin SGN 53 lupus nephritis 53 ABSORB clinical 53 MBP# [001] 53 ATIR TM 53 previously untreated follicular 53 mg/m2 cohort 53 talabostat 53 perifosine KRX 53 Trial Evaluating 53 Azilect ® 53 LymphoStat B 53 secondary efficacy endpoints 53 docetaxel Taxotere 53 RH1 53 cisplatin vinorelbine 53 Phase III Clinical Trials 53 ELND# 53 XL# XL# XL# 53 dextromethorphan quinidine 53 evaluating Actimmune 53 evaluating Vectibix 53 COSIRA trial 53 RRMS patients 53 CAMMS# 53 CBLC# 53 chemoradiotherapy 53 CORLUX 53 icatibant 53 HCV infected 53 DB# [003] 53 Fast Tracked Phase 52 FOLFIRI chemotherapy 52 refractory chronic lymphocytic 52 randomized controlled trial 52 KNS # 52 GV# [001] 52 candidate CRLX# 52 prostate cancer AIPC 52 GEM OS2 52 Nexavar ® 52 novel VDA molecule 52 ONGLYZA ™ 52 PEG IFN 52 abiraterone acetate 52 ONCONASE 52 BiTE antibody MT# 52 hematological cancers 52 Neulasta ® 52 II Clinical Trial 52 SABCS 52 Zavesca R 52 injectable enzyme 52 BEXXAR 52 CCX# B 52 pegylated interferon alfa 2b 52 metaglidasen 52 ANA# 52 rituximab 52 cell lung cancer 52 intravenous belinostat 52 PROVENGE 52 relapsed APL 52 OXi# 52 HGS ETR1 mapatumumab 52 AZILECT R 52 R roscovitine CDK cyclin 52 Bayer HealthCare Onyx Pharmaceuticals